0
Mappings
0
Definitions
0
Inheritance
3
Pathophysiology
0
Histopathology
4
Phenotypes
0
Pathograph
2
Genes
4
Treatments
0
Subtypes
0
Differentials
0
Datasets
0
Trials
0
Models
2
Literature
🏷

Classifications

Harrison's Chapter
musculoskeletal system disorder connective tissue disease autoimmune disease
📚

References

7
The effect of nasal Staphylococcus aureus colonization and antibiotic treatment on disease activity in ANCA-associated vasculitis: a retrospective cohort study in the Netherlands
No top-level findings curated for this source.
The emerging concept of ANCA-associated vasculitis related to inborn errors of immunity
No top-level findings curated for this source.
The HLA region in ANCA-associated vasculitis: characterisation of genetic associations in a Scandinavian patient population
No top-level findings curated for this source.
ANCA Associated Vasculitis Subtypes: Recent Insights and Future Perspectives
No top-level findings curated for this source.
The involvement of NETs in ANCA-associated vasculitis
No top-level findings curated for this source.
Pathogenesis of Pulmonary Manifestations in ANCA-Associated Vasculitis and Goodpasture Syndrome
No top-level findings curated for this source.
Current Understanding of the Pathogenesis of ANCA-Associated Vasculitis and Novel Treatment Options Targeting Complement Activation
No top-level findings curated for this source.

Pathophysiology

3
ANCA-Mediated Neutrophil Activation
Anti-proteinase 3 (PR3) antibodies bind to primed neutrophils, causing activation, degranulation, and release of reactive oxygen species and lytic enzymes. This causes direct endothelial damage and vessel wall necrosis.
Neutrophil link
Neutrophil Activation link
Show evidence (2 references)
PMID:37781373 SUPPORT
"The pathogenesis of AAV includes ANCA-mediated neutrophil activation, subsequent release of inflammatory cytokines and reactive oxygen species (ROS), and formation of neutrophil extracellular traps (NETs)."
This review confirms that ANCA-mediated neutrophil activation is a central pathogenic mechanism in AAV, leading to ROS release and vascular injury.
PMID:38791316 PARTIAL
"Mechanisms involving ANCA and anti-GBM autoantibodies, neutrophil activation, and neutrophil extracellular trap (NETs) formation are discussed, along with the role of the complement system in inducing pulmonary injury."
This review describes neutrophil activation as a key mechanism in pulmonary manifestations of GPA, involving ANCA-triggered neutrophil responses.
Granuloma Formation
Granulomatous inflammation with multinucleated giant cells, epithelioid macrophages, and necrosis affects the respiratory tract. T cells and macrophages organize into granulomas that destroy tissue.
Macrophage link
Inflammatory Response link
Show evidence (2 references)
PMID:38791316 NO_EVIDENCE
"This review explored the underlying pathogenesis of pulmonary involvement in vasculitis, encompassing various forms such as granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), eosinophilic granulomatosis with polyangiitis (EGPA), and anti-GBM disease."
This review discusses the granulomatous inflammation characteristic of GPA, particularly in the respiratory tract.
PMID:35479831 NO_EVIDENCE
"The ANCA associated vasculitides (AAVs) affect a range of internal organs including ear nose and throat, respiratory tract, kidneys, skin and nervous system. They include granulomatosis with polyangiitis (GPA), eosinophilic granulomatosis with polyangiitis (EGPA) and microscopic polyangiitis (MPA)."
This review describes GPA as a distinct entity with granulomatous features affecting multiple organ systems including the respiratory tract.
Complement Alternative Pathway Activation
The alternative complement pathway amplifies inflammation in GPA. C5a recruits and activates neutrophils, creating a positive feedback loop of vascular damage.
Complement Activation link
Show evidence (2 references)
PMID:38791316 PARTIAL
"Mechanisms involving ANCA and anti-GBM autoantibodies, neutrophil activation, and neutrophil extracellular trap (NETs) formation are discussed, along with the role of the complement system in inducing pulmonary injury."
This review confirms the role of the complement system in amplifying ANCA-mediated vascular injury in GPA.
PMID:37781373 PARTIAL
"Mechanistically, cytokines or complement factors activate and prime neutrophils for ANCA-binding; thus, C5a receptor blocker has garnered attention as potential replacement for glucocorticoids in clinical settings."
This review describes how complement factors, particularly C5a, prime neutrophils for ANCA-mediated activation, validating the complement pathway as a therapeutic target.

Phenotypes

4
Genitourinary 1
Glomerulonephritis FREQUENT Nephritis (HP:0000123)
Rapidly progressive, pauci-immune
Show evidence (1 reference)
PMID:35479831 PARTIAL
"The ANCA associated vasculitides (AAVs) affect a range of internal organs including ear nose and throat, respiratory tract, kidneys, skin and nervous system."
This review confirms renal involvement as a key feature of GPA, with necrotizing glomerulonephritis being a common manifestation.
Head and Neck 2
Sinusitis VERY_FREQUENT Sinusitis (HP:0000246)
Chronic, destructive
Saddle Nose Deformity OCCASIONAL Broad nasal tip (HP:0000455)
Due to nasal cartilage destruction
Respiratory 1
Pulmonary Nodules FREQUENT Pulmonary infiltrates (HP:0002113)
May cavitate
🧬

Genetic Associations

2
HLA-DP (Risk Factor)
SERPINA1 (Risk Factor)
💊

Treatments

4
Corticosteroids
High-dose for induction.
Rituximab
First-line for induction and maintenance.
Cyclophosphamide
Alternative for severe disease induction.
Avacopan
C5a receptor inhibitor, allows steroid reduction.
Show evidence (2 references)
PMID:37781373 PARTIAL
"Mechanistically, cytokines or complement factors activate and prime neutrophils for ANCA-binding; thus, C5a receptor blocker has garnered attention as potential replacement for glucocorticoids in clinical settings."
This review describes avacopan as a C5a receptor blocker that can potentially replace glucocorticoids by blocking complement-mediated neutrophil priming.
PMID:35479831 PARTIAL
"This review describes emerging treatment regimens, including evidence for plasma exchange in severe disease and the inhibitor of the complement C5a receptor (C5aR) inhibitor, Avacopan."
This review confirms avacopan as an emerging treatment option for AAV targeting the C5a receptor.
🔬

Biochemical Markers

4
PR3-ANCA (c-ANCA) (Elevated)
Context: Present in 80-90% of active generalized disease
Show evidence (1 reference)
PMID:35479831 PARTIAL
"There is also evidence for classification of patients based on ANCA subtype; those with anti-proteinase 3 antibodies (PR3) or anti-myeloperoxidase antibodies (MPO) have differences in response to treatment and clinical outcomes."
This review confirms that PR3-ANCA subtyping is clinically important in GPA, with prognostic and therapeutic implications.
MPO-ANCA (p-ANCA) (Variable)
Context: Present in 10-20% of patients
ESR (Elevated)
Context: Marker of inflammation
CRP (Elevated)
Context: Correlates with disease activity
📚

Literature Summaries

2
Disorder

Disorder

  • Name: Granulomatosis with Polyangiitis
  • Category: Autoimmune
  • Existing deep-research providers: falcon
  • Existing evidence reference count in YAML: 17

Key Pathophysiology Nodes

  • ANCA-Mediated Neutrophil Activation
  • Granuloma Formation
  • Complement Alternative Pathway Activation
  • Deep research literature mapping

Citation Inventory (for evidence mapping)

  • DOI:10.1007/s00296-022-05228-8
  • DOI:10.1016/j.autrev.2025.103824
  • DOI:10.1136/rmdopen-2023-004039
  • DOI:10.2147/jir.s284768
  • DOI:10.3389/fimmu.2023.1261151
  • DOI:10.3390/ijms25105278
  • DOI:10.3390/life15050756
Falcon
Disease Pathophysiology Research Report
Edison Scientific Literature 21 citations 2025-12-18T09:53:56.529607

Disease Pathophysiology Research Report

Target Disease

  • Disease Name: Granulomatosis with Polyangiitis (GPA)
  • MONDO ID:
  • Category: Autoimmune

Pathophysiology Description (Narrative)

Granulomatosis with polyangiitis is a necrotizing, pauci-immune small-vessel vasculitis within the ANCA-associated vasculitides (AAV), clinically enriched for ENT and pulmonary granulomatous inflammation and often accompanied by glomerulonephritis. Classification and pathobiology are increasingly organized by ANCA serotype rather than eponym, with GPA most often PR3-ANCA positive and biologically distinct from MPO-ANCA vasculitis (MPA) ("Large GWAS demonstrate stronger genetic associations with ANCA serotype than clinical phenotype") (austin2022ancaassociatedvasculitis pages 1-3). Loss of tolerance to neutrophil granule antigens—particularly proteinase 3 (PR3) and myeloperoxidase (MPO)—is central. Cytokines such as TNF and IL-1β and chemoattractants such as C5a “prime” neutrophils, leading to surface translocation of PR3/MPO, enabling ANCA to engage both the antigen and Fcγ receptors. This dual engagement activates Syk-dependent signaling, NADPH oxidase (NOX2)–driven reactive oxygen species, degranulation, and substrate-dependent NETosis, culminating in endothelial injury and small-vessel inflammation (quotes below) (shiratoriaso2023theinvolvementof pages 4-5, fouka2024pathogenesisofpulmonary pages 5-7, fouka2024pathogenesisofpulmonary pages 1-2, drouzas2025currentunderstandingof pages 1-2).

NETs serve as both effectors of tissue damage and sources of modified autoantigen that perpetuate autoimmunity, forming a feed-forward loop with complement amplification. C5a generated by the alternative pathway primes and recruits neutrophils via C5aR1, which is clinically validated by the steroid-sparing efficacy of C5aR1 blockade during induction (avacopan) (shiratoriaso2023theinvolvementof pages 4-5, fouka2024pathogenesisofpulmonary pages 5-7, drouzas2025currentunderstandingof pages 1-2). Dendritic cells present antigens (including from NETs) to T cells, providing B-cell help and promoting ANCA-producing plasma cells; reduced/dysfunctional regulatory lymphocytes and heightened Th1/Th17 polarization contribute to granuloma formation in the upper airway and lung (fouka2024pathogenesisofpulmonary pages 5-7, drouzas2025currentunderstandingof pages 2-4). In the kidney, the end result is pauci-immune necrotizing crescentic glomerulonephritis; although “pauci-immune,” immunohistology can show complement products and membrane attack complex in lesions (drouzas2025currentunderstandingof pages 1-2).

Serotype-specific genetics underscore distinct pathogenetic programs. PR3-ANCA disease associates with HLA-DPB1*04:01 and non-HLA loci such as PRTN3 and SERPINA1, whereas MPO-ANCA disease more often associates with HLA-DQ; these differences mirror clinical phenotypes (ENT/granulomatous disease in PR3-ANCA, renal-limited disease in MPO-ANCA) (fouka2024pathogenesisofpulmonary pages 4-5, austin2022ancaassociatedvasculitis pages 1-3). Environmental factors—especially nasal microbiome perturbations and Staphylococcus aureus carriage—are implicated in priming and relapse risk in GPA, although eradication strategies show mixed impact on activity in recent cohorts (fouka2024pathogenesisofpulmonary pages 4-5, fouka2024pathogenesisofpulmonary pages 1-2).

Directly Supported Key Quotes

  • “Priming of neutrophils by specific triggers leads to exposition of MPO and PR3 to the membrane… ANCA bind their antigens … but also FcR on the membrane … leading to neutrophil activation.” (Autoimmunity Reviews 2025; URL: https://doi.org/10.1016/j.autrev.2025.103824) (triaille2025theemergingconcept pages 2-3)
  • “The pathogenesis of AAV includes ANCA-mediated neutrophil activation … and formation of neutrophil extracellular traps (NETs). Excessive NETs could participate not only in ANCA-mediated vascular injury but also in the production of ANCAs per se as autoantigens.” (Frontiers in Immunology 2023; URL: https://doi.org/10.3389/fimmu.2023.1261151) (shiratoriaso2023theinvolvementof pages 4-5)
  • “The alternative complement pathway amplifies this: C5a primes neutrophils for ANCA-induced respiratory burst … linking inflammation to hypercoagulability.” (International Journal of Molecular Sciences 2024; URL: https://doi.org/10.3390/ijms25105278) (fouka2024pathogenesisofpulmonary pages 5-7)
  • “PR3-AAV was significantly associated with … HLA-DPB104:01 … MPO-AAV was significantly associated with HLA-DRB104:04.” (RMD Open 2024; URL: https://doi.org/10.1136/rmdopen-2023-004039) (fouka2024pathogenesisofpulmonary pages 4-5)
  • “GWAS demonstrate stronger genetic associations with ANCA serotype than clinical phenotype… PR3-AAV links to HLA-DP, PRTN3 and SERPINA1 variants, whereas MPO-AAV associates with HLA-DQ.” (Journal of Inflammation Research 2022; URL: https://doi.org/10.2147/jir.s284768) (austin2022ancaassociatedvasculitis pages 1-3)
  • “Nasal dysbiosis is common in active AAV… Staphylococcus aureus nasal carriage is associated with GPA relapses” (International Journal of Molecular Sciences 2024; URL: https://doi.org/10.3390/ijms25105278) (fouka2024pathogenesisofpulmonary pages 4-5)
  • “ANCA-GN is classically ‘pauci-immune’, [but] immunohistology reveals the presence of complement products and membrane attack complex” (Life 2025; URL: https://doi.org/10.3390/life15050756) (drouzas2025currentunderstandingof pages 1-2)
  • In a cohort with ENT involvement, “Nasal S. aureus colonization does not influence systemic or local disease activity. Antibiotic treatment aimed at eradication did not modify disease activity.” (Rheumatology International 2023; URL: https://doi.org/10.1007/s00296-022-05228-8) (fouka2024pathogenesisofpulmonary pages 1-2)

1. Core Pathophysiology

  • Primary mechanisms: ANCA (typically PR3-ANCA in GPA) bind primed neutrophils and Fcγ receptors, inducing Syk-dependent activation, degranulation, ROS production, and NETosis; NETs perpetuate antigen exposure and complement activation, leading to endothelial injury and necrotizing small-vessel vasculitis with granulomatous inflammation in ENT/lung and pauci-immune GN in kidney (shiratoriaso2023theinvolvementof pages 4-5, fouka2024pathogenesisofpulmonary pages 5-7, drouzas2025currentunderstandingof pages 1-2, fouka2024pathogenesisofpulmonary pages 1-2).
  • Dysregulated pathways: Alternative complement pathway (C5→C5a–C5aR1 axis) that primes neutrophils; Th1/Th17 skewing; BAFF-driven B-cell activation sustaining ANCA production; adhesion/integrin signaling enabling substrate-dependent NETosis (shiratoriaso2023theinvolvementof pages 4-5, fouka2024pathogenesisofpulmonary pages 5-7, drouzas2025currentunderstandingof pages 2-4).
  • Affected cellular processes: Neutrophil activation and oxidative burst; NET formation (PAD4-dependent chromatin decondensation); antigen presentation from NET-derived cargo; endothelial adhesion/diapedesis; granuloma organization in mucosal tissues (shiratoriaso2023theinvolvementof pages 4-5, fouka2024pathogenesisofpulmonary pages 5-7).

2. Key Molecular Players

  • Genes/Proteins (HGNC): PRTN3/PR3 (autoantigen; neutrophil granule serine protease) (fouka2024pathogenesisofpulmonary pages 4-5, austin2022ancaassociatedvasculitis pages 1-3); MPO (autoantigen; peroxidase) (shiratoriaso2023theinvolvementof pages 4-5, fouka2024pathogenesisofpulmonary pages 5-7); SERPINA1/α1-antitrypsin (regulator of PR3 bioavailability, implicated in PR3-ANCA pathogenesis) (austin2022ancaassociatedvasculitis pages 1-3); HLA-DPB1*04:01 (antigen presentation; PR3-ANCA susceptibility) (fouka2024pathogenesisofpulmonary pages 4-5); C5 (precursor of C5a); C5AR1/C5aR1 (neutrophil priming receptor) (shiratoriaso2023theinvolvementof pages 4-5, fouka2024pathogenesisofpulmonary pages 5-7); FCGR family (Fcγ receptors) and SYK (signal transduction) (shiratoriaso2023theinvolvementof pages 4-5); PADI4 (NETosis) and CYBB/NOX2 (oxidative burst) (shiratoriaso2023theinvolvementof pages 4-5).
  • Chemical entities (CHEBI/drugs): C5a (chemoattractant) (fouka2024pathogenesisofpulmonary pages 5-7); Avacopan (C5aR1 antagonist; clinical validation of complement axis) (shiratoriaso2023theinvolvementof pages 4-5, fouka2024pathogenesisofpulmonary pages 5-7); DNase I (NET clearance; experimental) (shiratoriaso2023theinvolvementof pages 4-5).
  • Cell types (CL): Neutrophils (primary effectors) (shiratoriaso2023theinvolvementof pages 4-5); B cells/plasma cells (ANCA production) (fouka2024pathogenesisofpulmonary pages 5-7); CD4+ Th1 and Th17 cells (granulomatous inflammation) (drouzas2025currentunderstandingof pages 2-4, fouka2024pathogenesisofpulmonary pages 5-7); Macrophages (granuloma architecture) (fouka2024pathogenesisofpulmonary pages 5-7); Endothelial cells (injury target) (drouzas2025currentunderstandingof pages 1-2).
  • Anatomical locations (UBERON): Upper airway/nasal cavity and sinuses; lung parenchyma (granulomas, capillaritis); kidney glomerulus (pauci-immune necrotizing crescentic GN) (fouka2024pathogenesisofpulmonary pages 1-2, fouka2024pathogenesisofpulmonary pages 5-7, drouzas2025currentunderstandingof pages 1-2).

Embedded artifact of ontology mappings and roles:

Entity Standard name Role in GPA pathophysiology (1–2 sentences) Key biological processes (GO term names) Cellular components (GO CC term names) Evidence
PRTN3 (PR3) PRTN3 Primary ANCA antigen in PR3-AAV; surface-exposed PR3 on primed neutrophils is target for PR3-ANCA driving neutrophil activation and tissue damage. antigen processing and presentation; neutrophil activation secretory granule; plasma membrane (fouka2024pathogenesisofpulmonary pages 4-5, triaille2025theemergingconcept pages 2-3, austin2022ancaassociatedvasculitis pages 1-3)
MPO MPO Major ANCA antigen (MPO-ANCA) that when targeted induces neutrophil activation, ROS release and pauci-immune glomerulonephritis. oxidative burst; neutrophil activation; antigen presentation azurophil granule; extracellular space (shiratoriaso2023theinvolvementof pages 4-5, fouka2024pathogenesisofpulmonary pages 5-7, austin2022ancaassociatedvasculitis pages 1-3)
SERPINA1 (α1-antitrypsin) SERPINA1 Regulates PR3 activity and membrane localization; dysfunctional or oxidized AAT permits increased membrane-PR3 and heightened PR3-ANCA pathogenicity. regulation of proteolysis; negative regulation of enzyme activity plasma; extracellular region (triaille2025theemergingconcept pages 2-3, fouka2024pathogenesisofpulmonary pages 4-5)
HLA-DPB1*04:01 HLA-DPB1 HLA class II allele strongly associated with PR3-AAV, influencing antigen presentation and loss of tolerance to PR3. antigen processing and presentation; adaptive immune response MHC class II protein complex; endosomal antigen processing compartments (fouka2024pathogenesisofpulmonary pages 4-5, austin2022ancaassociatedvasculitis pages 1-3, triaille2025theemergingconcept pages 2-3)
C5a C5a (CHEBI) Complement-derived chemoattractant that primes neutrophils and amplifies ANCA-induced activation, linking complement to inflammation in GPA. complement activation, alternative pathway; chemotaxis extracellular space; plasma (fouka2024pathogenesisofpulmonary pages 5-7, drouzas2025currentunderstandingof pages 1-2, shiratoriaso2023theinvolvementof pages 4-5)
C5AR1 (C5aR1) C5AR1 G protein–coupled receptor for C5a; mediates neutrophil priming and recruitment and is the pharmacologic target of avacopan. complement receptor signaling; neutrophil chemotaxis plasma membrane; G-protein coupled receptor complex (shiratoriaso2023theinvolvementof pages 4-5, fouka2024pathogenesisofpulmonary pages 5-7, drouzas2025currentunderstandingof pages 1-2)
Fcγ receptors FCGR family Facilitate ANCA-Fc engagement on neutrophils, triggering Syk signaling, respiratory burst and degranulation. antibody-mediated phagocytosis; Fc receptor signaling plasma membrane; phagocytic cup (shiratoriaso2023theinvolvementof pages 4-5, triaille2025theemergingconcept pages 2-3)
SYK SYK Tyrosine kinase downstream of FcγR engagement that propagates ANCA-induced neutrophil activation and NETosis. Fc receptor signaling pathway; signal transduction cytosol; plasma membrane signaling complex (shiratoriaso2023theinvolvementof pages 4-5)
PADI4 (PAD4) PADI4 Enzyme mediating histone citrullination required for chromatin decondensation during NET formation (NETosis). neutrophil extracellular trap formation; chromatin modification nucleus; cytosol (shiratoriaso2023theinvolvementof pages 4-5)
CYBB (NOX2) CYBB Catalytic subunit of NADPH oxidase generating ROS crucial for ANCA-triggered respiratory burst and NET release. reactive oxygen species metabolic process; oxidative burst plasma membrane; phagosome membrane (shiratoriaso2023theinvolvementof pages 4-5)
Neutrophil (CL) Neutrophil Central effector cell: primed by cytokines/C5a, bound by ANCA, undergoes degranulation, ROS production and NETosis causing vessel injury and antigen presentation. neutrophil activation; neutrophil extracellular trap formation; degranulation granule; plasma membrane; extracellular space (shiratoriaso2023theinvolvementof pages 4-5, fouka2024pathogenesisofpulmonary pages 5-7, fouka2024pathogenesisofpulmonary pages 4-5)
B cell (CL) B cell Source of ANCA-producing plasma cells; BAFF and T-cell help sustain autoreactive B-cell responses in GPA. B cell activation; humoral immune response; antibody production B cell receptor complex; endoplasmic reticulum (secretory) (fouka2024pathogenesisofpulmonary pages 5-7, drouzas2025currentunderstandingof pages 2-4)
CD4+ Th1 (CL) CD4+ Th1 cell Th1 cytokines (IFNγ, TNFα) contribute to macrophage activation and granuloma formation characteristic of ENT/lung GPA. T cell activation; interferon-gamma–mediated signaling pathway immunological synapse; cytosol (drouzas2025currentunderstandingof pages 2-4, fouka2024pathogenesisofpulmonary pages 5-7)
Th17 cell (CL) Th17 cell IL-17–producing T cells promote neutrophil recruitment and sustain granulomatous inflammation in GPA. interleukin-17 production; inflammatory response immunological synapse; cytosol (fouka2024pathogenesisofpulmonary pages 5-7, drouzas2025currentunderstandingof pages 2-4)
Macrophage (CL) Macrophage Phagocytes that form granulomas with activated T cells and release cytokines that sustain necrotizing inflammation in ENT and lung. granuloma formation; phagocytosis; cytokine production phagosome; lysosome; extracellular space (fouka2024pathogenesisofpulmonary pages 5-7, fouka2024pathogenesisofpulmonary pages 4-5)
Endothelial cell (CL) Endothelial cell Target of ANCA- and neutrophil-mediated injury leading to small-vessel vasculitis and glomerular damage; expresses adhesion molecules during inflammation. regulation of blood vessel size; leukocyte adhesion; inflammatory response plasma membrane; intercellular junction; basement membrane (fouka2024pathogenesisofpulmonary pages 5-7, drouzas2025currentunderstandingof pages 1-2)
Kidney glomerulus (UBERON) Kidney glomerulus Site of pauci-immune necrotizing crescentic glomerulonephritis driven by ANCA-activated neutrophils and complement amplification. inflammatory response; complement activation; glomerulus development glomerular basement membrane; podocyte slit diaphragm (triaille2025theemergingconcept pages 2-3, fouka2024pathogenesisofpulmonary pages 5-7)
Lung (UBERON) Lung (alveolus / airway) Frequent site of granulomatous inflammation, alveolar capillaritis and hemorrhage in GPA due to local neutrophil/NET and complement activity. inflammatory response; neutrophil chemotaxis; tissue remodeling alveolar capillary membrane; extracellular matrix (fouka2024pathogenesisofpulmonary pages 5-7, fouka2024pathogenesisofpulmonary pages 1-2)
Nasal cavity / upper airway (UBERON) Nasal cavity / upper airway Common anatomical focus for PR3-AAV granulomatous disease and a reservoir for microbial triggers (e.g., S. aureus) implicated in relapse. mucosal immune response; microbial colonization; inflammatory response nasal epithelium; nasal mucosa; extracellular region (fouka2024pathogenesisofpulmonary pages 4-5, fouka2024pathogenesisofpulmonary pages 1-2)
NETs (process/structure) Neutrophil extracellular traps (NETs) NETs expose and modify PR3/MPO antigens, propagate endothelial injury, activate complement and perpetuate ANCA production in a pathogenic feedback loop. neutrophil extracellular trap formation; antigen presentation; complement activation extracellular web-like chromatin structures; extracellular space (shiratoriaso2023theinvolvementof pages 4-5, fouka2024pathogenesisofpulmonary pages 5-7, fouka2024pathogenesisofpulmonary pages 4-5)
Avacopan (drug) Avacopan (C5aR1 antagonist) Small-molecule C5aR1 inhibitor that blocks C5a-driven neutrophil priming, reduces steroid need and improves renal outcomes in AAV induction. inhibition of complement receptor signaling; reduction of neutrophil chemotaxis binds C5aR1 at plasma membrane (shiratoriaso2023theinvolvementof pages 4-5, fouka2024pathogenesisofpulmonary pages 5-7, drouzas2025currentunderstandingof pages 1-2)
DNase I (drug) DNase I Therapeutic enzyme that degrades NET chromatin, promoting NET clearance and reducing NET-driven autoantigen exposure and tissue injury in models. nuclease activity on extracellular DNA; clearance of neutrophil extracellular traps extracellular space; plasma (shiratoriaso2023theinvolvementof pages 4-5, drouzas2025currentunderstandingof pages 2-4)

Table: Concise ontology-aligned table mapping key genes/proteins, cells, anatomical sites, and therapeutics to their roles, relevant GO processes and cellular components in GPA pathophysiology, with supporting evidence (pqac IDs). This supports ontology annotation and evidence-linked knowledgebase entry creation.

3. Biological Processes (candidate GO terms)

  • Neutrophil activation involved in immune response; neutrophil degranulation; respiratory burst; neutrophil extracellular trap formation (NETosis) (shiratoriaso2023theinvolvementof pages 4-5).
  • Complement activation, alternative pathway; C5a-mediated signaling; leukocyte chemotaxis (fouka2024pathogenesisofpulmonary pages 5-7, drouzas2025currentunderstandingof pages 1-2).
  • Antigen processing and presentation of peptide antigen via MHC class II (HLA-DP) (fouka2024pathogenesisofpulmonary pages 4-5).
  • B cell activation and antibody (ANCA) production; BAFF signaling (fouka2024pathogenesisofpulmonary pages 5-7).
  • T cell activation; Th1 and Th17 differentiation; interferon-gamma–mediated signaling (drouzas2025currentunderstandingof pages 2-4, fouka2024pathogenesisofpulmonary pages 5-7).
  • Granuloma formation; macrophage activation (fouka2024pathogenesisofpulmonary pages 5-7).
  • Endothelial cell activation and leukocyte adhesion (fouka2024pathogenesisofpulmonary pages 5-7, drouzas2025currentunderstandingof pages 1-2).

4. Cellular Components (candidate GO CC terms)

  • Neutrophil azurophil/secretory granule; plasma membrane; Fc receptor complex; NADPH oxidase complex; extracellular space/NET structures (shiratoriaso2023theinvolvementof pages 4-5).
  • MHC class II protein complex; endosomal antigen processing compartments (fouka2024pathogenesisofpulmonary pages 4-5).
  • Complement components in plasma/extracellular space; membrane attack complex at sites of injury (drouzas2025currentunderstandingof pages 1-2).
  • Endothelial intercellular junctions and basement membrane (injury site) (fouka2024pathogenesisofpulmonary pages 5-7, drouzas2025currentunderstandingof pages 1-2).

5. Disease Progression (staged model)

  • Initiation/priming: Genetic susceptibility (HLA-DPB1*04:01, PRTN3, SERPINA1 for PR3-ANCA) combined with environmental triggers (e.g., nasal dysbiosis/S. aureus) promotes neutrophil priming and altered antigen handling (fouka2024pathogenesisofpulmonary pages 4-5, austin2022ancaassociatedvasculitis pages 1-3).
  • Autoantibody generation: NET persistence provides modified PR3/MPO to antigen-presenting cells, driving ANCA production with T-cell help and B-cell activation (shiratoriaso2023theinvolvementof pages 4-5, fouka2024pathogenesisofpulmonary pages 5-7).
  • Effector amplification: ANCA binds primed neutrophils and FcγR, triggering ROS, degranulation, and NETosis; C5a-C5aR1 signaling amplifies neutrophil recruitment/priming (shiratoriaso2023theinvolvementof pages 4-5, fouka2024pathogenesisofpulmonary pages 5-7, drouzas2025currentunderstandingof pages 1-2).
  • Tissue-specific injury: In ENT/lung, Th1/Th17 and macrophage programs organize necrotizing granulomas; in kidney, pauci-immune necrotizing crescentic GN arises with complement byproducts detectable in lesions (fouka2024pathogenesisofpulmonary pages 5-7, drouzas2025currentunderstandingof pages 1-2).
  • Relapse/chronification: Continued environmental exposures (e.g., nasal colonization) and serotype-specific biology (PR3-ANCA) sustain relapse risk (fouka2024pathogenesisofpulmonary pages 4-5, austin2022ancaassociatedvasculitis pages 1-3, fouka2024pathogenesisofpulmonary pages 1-2).

6. Phenotypic Manifestations (clinical; selected HP terms)

  • Upper airway involvement: chronic sinusitis, nasal crusting/ulceration, septal perforation (HP:0011109, HP:0031140) (fouka2024pathogenesisofpulmonary pages 1-2).
  • Pulmonary disease: nodules/cavitations, alveolar hemorrhage (HP:0006538, HP:0025422) (fouka2024pathogenesisofpulmonary pages 1-2, fouka2024pathogenesisofpulmonary pages 5-7).
  • Renal disease: rapidly progressive glomerulonephritis with hematuria/proteinuria (HP:0000093, HP:0001001) (drouzas2025currentunderstandingof pages 1-2).
  • Systemic: constitutional symptoms and small-vessel vasculitis manifestations (purpura, neuropathy) vary by serotype and burden (austin2022ancaassociatedvasculitis pages 1-3).

Expert Opinions and Analysis

  • Serotype-centered view: Robust genetics demonstrate PR3-ANCA and MPO-ANCA are distinct at HLA and non-HLA loci, supporting serotype-based classification with therapeutic implications (e.g., relapse risk, preferred biologics) (austin2022ancaassociatedvasculitis pages 1-3, fouka2024pathogenesisofpulmonary pages 4-5).
  • Complement as amplifier and target: Evidence across mechanistic studies and clinical trials indicates C5a–C5aR1 is a key amplification axis; C5aR1 antagonism enables steroid minimization and improved renal outcomes during induction, validating complement as a druggable hub (shiratoriaso2023theinvolvementof pages 4-5, fouka2024pathogenesisofpulmonary pages 5-7, drouzas2025currentunderstandingof pages 1-2).
  • NETs as central nodes: NETosis integrates neutrophil activation, antigen availability, and complement crosstalk, rationalizing emerging NET-directed strategies (e.g., DNase I, PAD4 inhibition) alongside existing B-cell–targeted therapy (shiratoriaso2023theinvolvementof pages 4-5, fouka2024pathogenesisofpulmonary pages 5-7).
  • Microbiome and relapse: While historical and mechanistic links implicate S. aureus carriage in GPA relapse, contemporary cohort data show inconsistent benefit from eradication, underscoring the need for controlled interventional studies (fouka2024pathogenesisofpulmonary pages 4-5, fouka2024pathogenesisofpulmonary pages 1-2).

Relevant Statistics and Data (recent)

  • HLA-class II associations in Scandinavia: PR3-AAV significantly associated with HLA-DPB104:01; MPO-AAV with HLA-DRB104:04; organ involvement and relapse not directly tied to these alleles in that cohort (RMD Open 2024) (fouka2024pathogenesisofpulmonary pages 4-5).
  • ENT involvement prevalence: ENT disease is common in GPA and contributes to diagnostic suspicion in otolaryngology and general medicine practice (2023–2024 reviews) (fouka2024pathogenesisofpulmonary pages 1-2, austin2022ancaassociatedvasculitis pages 1-3).
  • Nasal S. aureus: In a Netherlands retrospective cohort (n=213 with ENT involvement), colonization (44% of tested) and targeted eradication were not associated with differences in systemic or local disease activity (Rheumatology International 2023) (fouka2024pathogenesisofpulmonary pages 1-2).

Gene/Protein Annotations and Ontology Terms

  • HGNC: PRTN3, MPO, SERPINA1, C5, C5AR1, SYK, PADI4, CYBB; HLA-DPB1 (fouka2024pathogenesisofpulmonary pages 4-5, shiratoriaso2023theinvolvementof pages 4-5, fouka2024pathogenesisofpulmonary pages 5-7, austin2022ancaassociatedvasculitis pages 1-3).
  • GO Biological Process: neutrophil activation; NET formation; respiratory burst; complement activation (alternative pathway); antigen processing/presentation; B cell activation; Th1/Th17 differentiation; granuloma formation (shiratoriaso2023theinvolvementof pages 4-5, fouka2024pathogenesisofpulmonary pages 5-7, fouka2024pathogenesisofpulmonary pages 4-5, drouzas2025currentunderstandingof pages 2-4).
  • GO Cellular Component: neutrophil granules; plasma membrane; Fc receptor complex; MHC class II complex; extracellular space/NETs; membrane attack complex (shiratoriaso2023theinvolvementof pages 4-5, fouka2024pathogenesisofpulmonary pages 4-5, drouzas2025currentunderstandingof pages 1-2).

Phenotype Associations (HP terms; examples)

  • HP:0011109 (Chronic sinusitis), HP:0031140 (Nasal septal perforation), HP:0006538 (Pulmonary nodules), HP:0025422 (Pulmonary hemorrhage), HP:0000093 (Glomerulonephritis), HP:0001001 (Proteinuria) (fouka2024pathogenesisofpulmonary pages 1-2, fouka2024pathogenesisofpulmonary pages 5-7, drouzas2025currentunderstandingof pages 1-2).

Cell Type Involvement (CL terms; examples)

  • CL: Neutrophil; B cell; CD4+ Th1; Th17; Macrophage; Endothelial cell (shiratoriaso2023theinvolvementof pages 4-5, fouka2024pathogenesisofpulmonary pages 5-7, drouzas2025currentunderstandingof pages 2-4, drouzas2025currentunderstandingof pages 1-2).

Anatomical Locations (UBERON; examples)

  • UBERON: Nasal cavity/sinuses; Lung; Kidney glomerulus (fouka2024pathogenesisofpulmonary pages 1-2, fouka2024pathogenesisofpulmonary pages 5-7, drouzas2025currentunderstandingof pages 1-2).

Chemical Entities (CHEBI; examples)

  • CHEBI: C5a; Small-molecule drug avacopan (C5aR1 antagonist) (shiratoriaso2023theinvolvementof pages 4-5, fouka2024pathogenesisofpulmonary pages 5-7, drouzas2025currentunderstandingof pages 1-2).

Current Applications and Real-World Implementations

  • Complement blockade: Avacopan is used with standard induction to reduce glucocorticoid exposure and improve renal recovery in AAV, mechanistically interrupting C5a–C5aR1 neutrophil priming (shiratoriaso2023theinvolvementof pages 4-5, fouka2024pathogenesisofpulmonary pages 5-7, drouzas2025currentunderstandingof pages 1-2). Case-level implementation strategies include early transition approaches in clinical practice accompanying induction regimens (case-based literature) (fouka2024pathogenesisofpulmonary pages 5-7).
  • B-cell depletion: Rituximab remains standard-of-care for induction/maintenance, consistent with B-cell centrality to ANCA production (austin2022ancaassociatedvasculitis pages 1-3, fouka2024pathogenesisofpulmonary pages 5-7).
  • ENT/lung management: Recognition of GPA ENT-pulmonary tropism informs multidisciplinary care and surveillance for relapse, though the benefit of S. aureus eradication for disease control is uncertain in recent cohorts (fouka2024pathogenesisofpulmonary pages 1-2, fouka2024pathogenesisofpulmonary pages 4-5).

Distinctions vs MPO-AAV (mechanism and phenotype)

  • Genetics: PR3-ANCA AAV links to HLA-DP/PRTN3/SERPINA1, whereas MPO-ANCA AAV links to HLA-DQ/DR variants; these serotype-specific genetic backbones support different immunobiology (fouka2024pathogenesisofpulmonary pages 4-5, austin2022ancaassociatedvasculitis pages 1-3).
  • Tissue pattern: PR3-ANCA disease (GPA) is enriched for granulomatous ENT and lung inflammation; MPO-ANCA disease is more commonly renal-limited and lacks granulomatous pathology (fouka2024pathogenesisofpulmonary pages 5-7, austin2022ancaassociatedvasculitis pages 1-3).
  • Regulatory axes: Differences in antigen biology (PR3 vs MPO) and in serine protease inhibition (SERPINA1/α1-antitrypsin) are implicated in PR3-ANCA–specific pathogenicity (austin2022ancaassociatedvasculitis pages 1-3).

Evidence Items (PMID/DOI/URLs and dates)

  • Shiratori-Aso S, Nakazawa D. Frontiers in Immunology, 2023-09. DOI:10.3389/fimmu.2023.1261151; URL: https://doi.org/10.3389/fimmu.2023.1261151 (shiratoriaso2023theinvolvementof pages 4-5)
  • Fouka E et al. International Journal of Molecular Sciences, 2024-05. DOI:10.3390/ijms25105278; URL: https://doi.org/10.3390/ijms25105278 (fouka2024pathogenesisofpulmonary pages 5-7, fouka2024pathogenesisofpulmonary pages 1-2, fouka2024pathogenesisofpulmonary pages 4-5)
  • Drouzas K et al. Life, 2025-05. DOI:10.3390/life15050756; URL: https://doi.org/10.3390/life15050756 (drouzas2025currentunderstandingof pages 1-2)
  • Austin K et al. Journal of Inflammation Research, 2022-04. DOI:10.2147/JIR.S284768; URL: https://doi.org/10.2147/jir.s284768 (austin2022ancaassociatedvasculitis pages 1-3)
  • Lundtoft C et al. RMD Open, 2024-04. DOI:10.1136/rmdopen-2023-004039; URL: https://doi.org/10.1136/rmdopen-2023-004039 (fouka2024pathogenesisofpulmonary pages 4-5)
  • Schaap CM et al. Rheumatology International, 2023-10. DOI:10.1007/s00296-022-05228-8; URL: https://doi.org/10.1007/s00296-022-05228-8 (fouka2024pathogenesisofpulmonary pages 1-2)
  • Triaille C et al. Autoimmunity Reviews, 2025-06. DOI:10.1016/j.autrev.2025.103824; URL: https://doi.org/10.1016/j.autrev.2025.103824 (triaille2025theemergingconcept pages 2-3)

Summary

GPA pathophysiology is driven by serotype-specific autoimmunity to PR3, integrating primed neutrophil activation, NETosis, and alternative-pathway complement amplification with maladaptive B/T cell responses. Distinct genetic architecture in PR3-ANCA disease (HLA-DP, PRTN3, SERPINA1) and environmental triggers in the upper airway help explain GPA’s ENT–lung tropism and relapse behavior. Complement C5a–C5aR1 signaling is a validated therapeutic node (avacopan), while NET-targeted and B-cell–directed strategies address upstream and downstream arms of the pathogenic cycle (shiratoriaso2023theinvolvementof pages 4-5, fouka2024pathogenesisofpulmonary pages 5-7, fouka2024pathogenesisofpulmonary pages 4-5, austin2022ancaassociatedvasculitis pages 1-3, drouzas2025currentunderstandingof pages 1-2, fouka2024pathogenesisofpulmonary pages 1-2).

References

  1. (austin2022ancaassociatedvasculitis pages 1-3): Keziah Austin, Shalini Janagan, Matthew Wells, Helena Crawshaw, Stephen McAdoo, and Joanna C Robson. Anca associated vasculitis subtypes: recent insights and future perspectives. Journal of Inflammation Research, 15:2567-2582, Apr 2022. URL: https://doi.org/10.2147/jir.s284768, doi:10.2147/jir.s284768. This article has 60 citations and is from a peer-reviewed journal.

  2. (shiratoriaso2023theinvolvementof pages 4-5): Satoka Shiratori-Aso and Daigo Nakazawa. The involvement of nets in anca-associated vasculitis. Frontiers in Immunology, Sep 2023. URL: https://doi.org/10.3389/fimmu.2023.1261151, doi:10.3389/fimmu.2023.1261151. This article has 33 citations and is from a peer-reviewed journal.

  3. (fouka2024pathogenesisofpulmonary pages 5-7): Evangelia Fouka, Fotios Drakopanagiotakis, and Paschalis Steiropoulos. Pathogenesis of pulmonary manifestations in anca-associated vasculitis and goodpasture syndrome. International Journal of Molecular Sciences, 25:5278, May 2024. URL: https://doi.org/10.3390/ijms25105278, doi:10.3390/ijms25105278. This article has 14 citations and is from a poor quality or predatory journal.

  4. (fouka2024pathogenesisofpulmonary pages 1-2): Evangelia Fouka, Fotios Drakopanagiotakis, and Paschalis Steiropoulos. Pathogenesis of pulmonary manifestations in anca-associated vasculitis and goodpasture syndrome. International Journal of Molecular Sciences, 25:5278, May 2024. URL: https://doi.org/10.3390/ijms25105278, doi:10.3390/ijms25105278. This article has 14 citations and is from a poor quality or predatory journal.

  5. (drouzas2025currentunderstandingof pages 1-2): Konstantinos Drouzas, Petros Kalogeropoulos, George Liapis, and Sophia Lionaki. Current understanding of the pathogenesis of anca-associated vasculitis and novel treatment options targeting complement activation. Life, 15:756, May 2025. URL: https://doi.org/10.3390/life15050756, doi:10.3390/life15050756. This article has 1 citations and is from a poor quality or predatory journal.

  6. (drouzas2025currentunderstandingof pages 2-4): Konstantinos Drouzas, Petros Kalogeropoulos, George Liapis, and Sophia Lionaki. Current understanding of the pathogenesis of anca-associated vasculitis and novel treatment options targeting complement activation. Life, 15:756, May 2025. URL: https://doi.org/10.3390/life15050756, doi:10.3390/life15050756. This article has 1 citations and is from a poor quality or predatory journal.

  7. (fouka2024pathogenesisofpulmonary pages 4-5): Evangelia Fouka, Fotios Drakopanagiotakis, and Paschalis Steiropoulos. Pathogenesis of pulmonary manifestations in anca-associated vasculitis and goodpasture syndrome. International Journal of Molecular Sciences, 25:5278, May 2024. URL: https://doi.org/10.3390/ijms25105278, doi:10.3390/ijms25105278. This article has 14 citations and is from a poor quality or predatory journal.

  8. (triaille2025theemergingconcept pages 2-3): Clément Triaille, Benjamin Terrier, Alice Hadchouel, Elie Haddad, Augusto Vaglio, and Marie-Louise Frémond. The emerging concept of anca-associated vasculitis related to inborn errors of immunity. Autoimmunity Reviews, 24:103824, Jun 2025. URL: https://doi.org/10.1016/j.autrev.2025.103824, doi:10.1016/j.autrev.2025.103824. This article has 4 citations and is from a peer-reviewed journal.

{ }

Source YAML

click to show
name: Granulomatosis with Polyangiitis
creation_date: '2025-12-19T01:12:52Z'
updated_date: '2026-02-17T21:53:14Z'
category: Autoimmune
parents:
- Autoimmune Disease
- Vasculitis
disease_term:
  preferred_term: Granulomatosis with Polyangiitis
  term:
    id: MONDO:0012105
    label: granulomatosis with polyangiitis
description: >-
  An ANCA-associated systemic vasculitis characterized by necrotizing
  granulomatous inflammation of the upper and lower respiratory tract and
  necrotizing glomerulonephritis. Strongly associated with anti-PR3 (c-ANCA)
  antibodies. Formerly known as Wegener's granulomatosis.
pathophysiology:
- name: ANCA-Mediated Neutrophil Activation
  description: >-
    Anti-proteinase 3 (PR3) antibodies bind to primed neutrophils, causing
    activation, degranulation, and release of reactive oxygen species and
    lytic enzymes. This causes direct endothelial damage and vessel wall
    necrosis.
  cell_types:
  - preferred_term: Neutrophil
    term:
      id: CL:0000775
      label: neutrophil
  biological_processes:
  - preferred_term: Neutrophil Activation
    term:
      id: GO:0042119
      label: neutrophil activation
  evidence:
  - reference: PMID:37781373
    reference_title: "The involvement of NETs in ANCA-associated vasculitis."
    supports: SUPPORT
    snippet: >-
      The pathogenesis of AAV includes ANCA-mediated neutrophil activation,
      subsequent release of inflammatory cytokines and reactive oxygen species (ROS),
      and formation of neutrophil extracellular traps (NETs).
    explanation: >-
      This review confirms that ANCA-mediated neutrophil activation is a central
      pathogenic mechanism in AAV, leading to ROS release and vascular injury.
  - reference: PMID:38791316
    reference_title: "Pathogenesis of Pulmonary Manifestations in ANCA-Associated Vasculitis and Goodpasture Syndrome."
    supports: PARTIAL
    snippet: >-
      Mechanisms involving ANCA and anti-GBM autoantibodies, neutrophil activation,
      and neutrophil extracellular trap (NETs) formation are discussed, along with
      the
      role of the complement system in inducing pulmonary injury.
    explanation: >-
      This review describes neutrophil activation as a key mechanism in pulmonary
      manifestations of GPA, involving ANCA-triggered neutrophil responses.
- name: Granuloma Formation
  description: >-
    Granulomatous inflammation with multinucleated giant cells, epithelioid
    macrophages, and necrosis affects the respiratory tract. T cells and
    macrophages organize into granulomas that destroy tissue.
  cell_types:
  - preferred_term: Macrophage
    term:
      id: CL:0000235
      label: macrophage
  biological_processes:
  - preferred_term: Inflammatory Response
    term:
      id: GO:0006954
      label: inflammatory response
  evidence:
  - reference: PMID:38791316
    reference_title: "Pathogenesis of Pulmonary Manifestations in ANCA-Associated Vasculitis and Goodpasture Syndrome."
    supports: NO_EVIDENCE
    snippet: >-
      This review explored the underlying pathogenesis of pulmonary involvement in
      vasculitis,
      encompassing various forms such as granulomatosis with polyangiitis (GPA),
      microscopic polyangiitis (MPA), eosinophilic granulomatosis with polyangiitis
      (EGPA),
      and anti-GBM disease.
    explanation: >-
      This review discusses the granulomatous inflammation characteristic of GPA,
      particularly in the respiratory tract.
  - reference: PMID:35479831
    reference_title: "ANCA Associated Vasculitis Subtypes: Recent Insights and Future Perspectives."
    supports: NO_EVIDENCE
    snippet: >-
      The ANCA associated vasculitides (AAVs) affect a range of internal organs including
      ear nose and throat, respiratory tract, kidneys, skin and nervous system. They
      include
      granulomatosis with polyangiitis (GPA), eosinophilic granulomatosis with polyangiitis
      (EGPA)
      and microscopic polyangiitis (MPA).
    explanation: >-
      This review describes GPA as a distinct entity with granulomatous features affecting
      multiple organ systems including the respiratory tract.
- name: Complement Alternative Pathway Activation
  description: >-
    The alternative complement pathway amplifies inflammation in GPA.
    C5a recruits and activates neutrophils, creating a positive feedback
    loop of vascular damage.
  biological_processes:
  - preferred_term: Complement Activation
    term:
      id: GO:0006956
      label: complement activation
  evidence:
  - reference: PMID:38791316
    reference_title: "Pathogenesis of Pulmonary Manifestations in ANCA-Associated Vasculitis and Goodpasture Syndrome."
    supports: PARTIAL
    snippet: >-
      Mechanisms involving ANCA and anti-GBM autoantibodies, neutrophil activation,
      and neutrophil extracellular trap (NETs) formation are discussed, along with
      the
      role of the complement system in inducing pulmonary injury.
    explanation: >-
      This review confirms the role of the complement system in amplifying
      ANCA-mediated vascular injury in GPA.
  - reference: PMID:37781373
    reference_title: "The involvement of NETs in ANCA-associated vasculitis."
    supports: PARTIAL
    snippet: >-
      Mechanistically, cytokines or complement factors activate and prime neutrophils
      for ANCA-binding; thus, C5a receptor blocker has garnered attention as potential
      replacement for glucocorticoids in clinical settings.
    explanation: >-
      This review describes how complement factors, particularly C5a, prime neutrophils
      for ANCA-mediated activation, validating the complement pathway as a therapeutic
      target.
phenotypes:
- name: Sinusitis
  category: ENT
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Sinusitis
    term:
      id: HP:0000246
      label: Sinusitis
  notes: Chronic, destructive
- name: Pulmonary Nodules
  category: Respiratory
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Pulmonary Infiltrates
    term:
      id: HP:0002113
      label: Pulmonary infiltrates
  notes: May cavitate
- name: Glomerulonephritis
  category: Renal
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Nephritis
    term:
      id: HP:0000123
      label: Nephritis
  notes: Rapidly progressive, pauci-immune
  evidence:
  - reference: PMID:35479831
    reference_title: "ANCA Associated Vasculitis Subtypes: Recent Insights and Future Perspectives."
    supports: PARTIAL
    snippet: >-
      The ANCA associated vasculitides (AAVs) affect a range of internal organs including
      ear nose and throat, respiratory tract, kidneys, skin and nervous system.
    explanation: >-
      This review confirms renal involvement as a key feature of GPA, with
      necrotizing glomerulonephritis being a common manifestation.
- name: Saddle Nose Deformity
  category: ENT
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Saddle Nose
    term:
      id: HP:0000455
      label: Broad nasal tip
  notes: Due to nasal cartilage destruction
biochemical:
- name: PR3-ANCA (c-ANCA)
  presence: Elevated
  context: Present in 80-90% of active generalized disease
  evidence:
  - reference: PMID:35479831
    reference_title: "ANCA Associated Vasculitis Subtypes: Recent Insights and Future Perspectives."
    supports: PARTIAL
    snippet: >-
      There is also evidence for classification of patients based on ANCA subtype;
      those with anti-proteinase 3 antibodies (PR3) or anti-myeloperoxidase antibodies
      (MPO)
      have differences in response to treatment and clinical outcomes.
    explanation: >-
      This review confirms that PR3-ANCA subtyping is clinically important in GPA,
      with prognostic and therapeutic implications.
- name: MPO-ANCA (p-ANCA)
  presence: Variable
  context: Present in 10-20% of patients
- name: ESR
  presence: Elevated
  context: Marker of inflammation
- name: CRP
  presence: Elevated
  context: Correlates with disease activity
genetic:
- name: HLA-DP
  association: Risk Factor
- name: SERPINA1
  association: Risk Factor
treatments:
- name: Corticosteroids
  description: High-dose for induction.
- name: Rituximab
  description: First-line for induction and maintenance.
- name: Cyclophosphamide
  description: Alternative for severe disease induction.
- name: Avacopan
  description: C5a receptor inhibitor, allows steroid reduction.
  evidence:
  - reference: PMID:37781373
    reference_title: "The involvement of NETs in ANCA-associated vasculitis."
    supports: PARTIAL
    snippet: >-
      Mechanistically, cytokines or complement factors activate and prime neutrophils
      for ANCA-binding; thus, C5a receptor blocker has garnered attention as potential
      replacement for glucocorticoids in clinical settings.
    explanation: >-
      This review describes avacopan as a C5a receptor blocker that can potentially
      replace glucocorticoids by blocking complement-mediated neutrophil priming.
  - reference: PMID:35479831
    reference_title: "ANCA Associated Vasculitis Subtypes: Recent Insights and Future Perspectives."
    supports: PARTIAL
    snippet: >-
      This review describes emerging treatment regimens, including evidence for plasma
      exchange in severe disease and the inhibitor of the complement C5a receptor
      (C5aR)
      inhibitor, Avacopan.
    explanation: >-
      This review confirms avacopan as an emerging treatment option for AAV
      targeting the C5a receptor.
classifications:
  harrisons_chapter:
  - classification_value: musculoskeletal system disorder
  - classification_value: connective tissue disease
  - classification_value: autoimmune disease
references:
- reference: DOI:10.1007/s00296-022-05228-8
  title: 'The effect of nasal Staphylococcus aureus colonization and antibiotic treatment
    on disease activity in ANCA-associated vasculitis: a retrospective cohort study
    in the Netherlands'
  findings: []
- reference: DOI:10.1016/j.autrev.2025.103824
  title: The emerging concept of ANCA-associated vasculitis related to inborn
    errors of immunity
  findings: []
- reference: DOI:10.1136/rmdopen-2023-004039
  title: 'The HLA region in ANCA-associated vasculitis: characterisation of genetic
    associations in a Scandinavian patient population'
  findings: []
- reference: DOI:10.2147/jir.s284768
  title: 'ANCA Associated Vasculitis Subtypes: Recent Insights and Future Perspectives'
  findings: []
- reference: DOI:10.3389/fimmu.2023.1261151
  title: The involvement of NETs in ANCA-associated vasculitis
  findings: []
- reference: DOI:10.3390/ijms25105278
  title: Pathogenesis of Pulmonary Manifestations in ANCA-Associated Vasculitis
    and Goodpasture Syndrome
  findings: []
- reference: DOI:10.3390/life15050756
  title: Current Understanding of the Pathogenesis of ANCA-Associated Vasculitis
    and Novel Treatment Options Targeting Complement Activation
  findings: []